Role of Electroencephalogram (EEG) and Magnetic Resonance Imaging (MRI) Findings in Early Recognition and Diagnosis of Neuronal Ceroid Lipofuscinosis Type 2 Disease
Restricted accessResearch articleFirst published online December, 2022
Role of Electroencephalogram (EEG) and Magnetic Resonance Imaging (MRI) Findings in Early Recognition and Diagnosis of Neuronal Ceroid Lipofuscinosis Type 2 Disease
Neuronal ceroid lipofuscinosis type 2 (CLN2) disease is a very rare neurodegenerative lysosomal storage disorder. Progression is rapid and irreversible, making early diagnosis crucial for timely treatment. A group of pediatric neurologists and neuroradiologists with expertise in CLN2 convened to discuss early electroencephalogram (EEG) and magnetic resonance imaging (MRI) findings in CLN2 diagnosis. Of 18 CLN2 cases, 16 (88.9%) had background slowing and 16 (88.9%) had epileptiform discharges on initial EEG. Seven of 17 (41.2%) patients who received intermittent low-frequency photic stimulation had a photoparoxysmal response. Initial MRIs showed subtle cerebellar (n = 14, 77.8%) or cerebral (n = 9, 50.0%) atrophy, white matter abnormalities (n = 11, 61.1%), and basal ganglia T2 hypointensity (n = 6, 33.3%), which became more apparent on follow-up MRI. The recognition of even subtle cerebellar atrophy and white matter signal changes in children aged 2-5 years who present with language delay, new-onset seizures, and an EEG with epileptiform discharges and background slowing should prompt investigation for CLN2. Because these early signs are not unique to CLN2, genetic testing is essential early in the diagnostic journey.
SimpsonNAWheelerEDPearceDA. Screening, diagnosis and epidemiology of Batten disease. Expert Opin Orphan Drugs. 2014;2(9):903‐910.
3.
FietzMAlSayedMBurkeD, et al. Diagnosis of neuronal ceroid lipofuscinosis type 2 (CLN2 disease): expert recommendations for early detection and laboratory diagnosis. Mol Genet Metab. 2016;119(1–2):160‐167.
SeranovaEConnollyKJZatykaM, et al. Dysregulation of autophagy as a common mechanism in lysosomal storage diseases. Essays Biochem. 2017;61(6):733‐749.
8.
SpecchioNPietrafusaNTrivisanoM. Changing times for CLN2 disease: the era of enzyme replacement therapy. Ther Clin Risk Manag. 2020;16:213‐222.
9.
GardnerEBaileyMSchulzAAristorenaMMillerNMoleSE. Mutation update: review of TPP1 gene variants associated with neuronal ceroid lipofuscinosis CLN2 disease. Hum Mutat. 2019;40(11):1924‐1938.
10.
Pérez-PoyatoMSMarfaMPAbizandaIF, et al. Late infantile neuronal ceroid lipofuscinosis: mutations in the CLN2 gene and clinical course in Spanish patients. J Child Neurol. 2013;28(4):470‐478.
11.
JohnsonAMMandelstamSAndrewsI, et al. Neuronal ceroid lipofuscinosis type 2: an Australian case series. J Paediatr Child Health. 2020;56(8):1210‐1218.
12.
WyrwichKWSchulzANickelM, et al. An adapted clinical measurement tool for the key symptoms of CLN2 disease. J Inborn Errors Metab Screen. 2018;6:1‐7.
13.
NickelMSimonatiAJacobyD, et al. Disease characteristics and progression in patients with late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease: an observational cohort study. Lancet Child Adolesc Health. 2018;2(8):582‐590.
14.
SchulzAAjayiTSpecchioN, et al. Study of intraventricular cerliponase alfa for CLN2 disease. N Eng J Med. 2018;378(20):1898‐1907.
15.
SchulzASpecchioNGissenP, et al. Persistent treatment effect of cerliponase alfa in children with CLN2 disease: a 3 year update from an ongoing multicenter extension study. Neuropediatrics. 2019;50(suppl 02):S1‐S55.
16.
AlbertDVYinHDe Los ReyesECVidaurreJ. Unique characteristics of the photoparoxysmal response in patients with neuronal ceroid lipofuscinosis type 2: can EEG be a biomarker?J Child Neurol. 2016;31(13):1475‐1482.
17.
MoleSESchulzABadoeE, et al. Guidelines on the diagnosis, clinical assessments, treatment and management for CLN2 disease patients. Orphanet J Rare Dis. 2021;16(1):185.
18.
PampiglioneGHardenA. Neurophysiological identification of a late infantile form of ‘neuronal lipidosis’. J Neurol Neurosurg Psychiatry. 1973;36(1):68‐74.
19.
JadavRHSinhaSYashaTC, et al. Clinical, electrophysiological, imaging, and ultrastructural description in 68 patients with neuronal ceroid lipofuscinoses and its subtypes. Pediatr Neurol. 2014;50(1):85‐95.
20.
VeneselliEBiancheriRBuoniSFoisA. Clinical and EEG findings in 18 cases of late infantile neuronal ceroid lipofuscinosis. Brain Dev. 2001;23(5):306‐311.
21.
NaqviSZBeachRLArmaoDMGreenwoodRS. Photoparoxysmal response in late infantile neuronal ceroid-lipofuscinosis. Pediatr Neurol. 1998;19(5):395‐398.
22.
SpecchioNBellusciMPietrafusaNTrivisanoMde PalmaLVigevanoF. Photosensitivity is an early marker of neuronal ceroid lipofuscinosis type 2 disease. Epilepsia. 2017;58(8):1380‐1388.
23.
Kasteleijn-Nolst TrenitéDRubboliGHirschE, et al. Methodology of photic stimulation revisited: updated European algorithm for visual stimulation in the EEG laboratory. Epilepsia. 2012;53(1):16‐24.
24.
KurataniJPearlPLSullivanL, et al. American Clinical Neurophysiology Society guideline 5: minimum technical standards for pediatric electroencephalography. J Clin Neurophysiol. 2016;33(4):320‐323.
25.
van WinOABarnesJGFerrierCFBoothFPrasadANKasteleijn-Nolst TreniteDGA. A study of the significance of photoparoxysmal responses and spontaneous epileptiform discharges in the EEG in childhood epilepsy. Epilepsy Behav. 2020;107:107046.
26.
ArdicliDHalilogluGGocmenRGunbeyCTopcuM. Unraveling neuronal ceroid lipofuscinosis type 2 (CLN2) disease: a tertiary center experience for determinants of diagnostic delay. Eur J Paediatr Neurol. 2021;33:94‐98.
27.
AydınKHavaliCKartalASerdaroğluAHaspolatŞ. MRI in CLN2 disease patients: subtle features that support an early diagnosis. Eur J Paediatr Neurol. 2020;28:228-236.
28.
Dozières-PuyravelBNasserHElmaleh-BergèsM, et al. Paediatric-onset neuronal ceroid lipofuscinosis: first symptoms and presentation at diagnosis. Dev Med Child Neurol. 2020;62(4):528‐530.
29.
BiswasAKrishnanPAmirabadiABlaserSMercimek-AndrewsSShroffM. Expanding the neuroimaging phenotype of neuronal ceroid lipofuscinoses. AJNR Am J Neuroradiol. 2020;41(10):1930‐1936.
30.
Uzun ÇiçekAAkdagECelebi ErdivanliO. Sociodemographic characteristics associated with speech and language delay and disorders. J Nerv Ment Dis. 2020;208(2):143‐146.
31.
McLaughlinMR. Speech and language delay in children. Am Fam Physician. 2011;83(10):1183‐1188.
32.
HirtzDAshwalSBergA, et al. Practice parameter: evaluating a first nonfebrile seizure in children: report of the quality standards subcommittee of the American Academy of Neurology, the Child Neurology Society, and the American Epilepsy Society. Neurology. 2000;55(5):616‐623.
33.
CoryellJGaillardWDShellhaasRA, et al. Neuroimaging of early life epilepsy. Pediatrics. 2018;142(3):e20180672.
34.
Mazurkiewicz-BełdzińskaMDel ToroMHaliloğluG, et al. Managing CLN2 disease: a treatable neurodegenerative condition among other treatable early childhood epilepsies. Expert Rev Neurother. 2021;21(11):1275-1282.
35.
ManickamKMcClainMRDemmerLA, et al. Exome and genome sequencing for pediatric patients with congenital anomalies or intellectual disability: an evidence-based clinical guideline of the American College of Medical Genetics and Genomics (ACMG). Genet Med. 2021;23(11):2029‐2037.
36.
Sánchez FernándezILoddenkemperTGaínza-LeinMSheidleyBRPoduriA. Diagnostic yield of genetic tests in epilepsy: a meta-analysis and cost-effectiveness study. Neurology. 2019;92(5):e418‐e428.
